PALVELLA THERAPEUTICS, INC. - 8-K Filing

FDA grants Priority Review for Palvella's QTORIN™ rapamycin NDA with a PDUFA target action date of February 28, 2027. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 28, 2026, 11:31 UTC

Tickers: $PVLA

Read the full article at SEC EDGAR

More Regulatory news

UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC